Anyone monitoring Ranbaxy’s shareholding pattern in December 2013 would have noticed a new entrant by the name of Silverstreet Developers with a 1.41% stake in the Daiichi Sankyo subsidiary. By March, the same entity had further raised its stake to 1.64%. Though not a significant jump, discerning investors would have known that something was up.
Will Sun rise again?
Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?
Summer wine and salad
Kishore Singh - January 19, 2015
A double topping for growth
Meghna Maiti - January 15, 2015
The million-dollar question: Is investing a game of luck or skill?
Shankar Sharma - May 04, 2021
Scriptures for success
Kripa Mahalingam - January 27, 2015
Every crisis is an opportunity, if you are on the right side of equities
Samir Arora - May 04, 2021